Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalbavancin for Pediatric Osteomyelitis
NCT02344511Phase 3Withdrawn
- Sponsor
- Durata Therapeutics
- Start
- Mar 2016
- Primary completion
- Oct 2018
- Modality
- Peptides, Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of dalbavancin in acute hematogenous osteomyelitis (AHO) (2 arms), sponsored by Durata Therapeutics. Primary endpoint: Number of patients with clinical improvement at Day 8. Planned start Mar 2016; status: withdrawn.
02
Drugs
dalbavancin
03
Conditions
acute hematogenous osteomyelitis (AHO)
Beyond the preview
Go deeper on NCT02344511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02344511.